Lumigan and Uveitis - a phase IV clinical study of FDA data

Summary:

Uveitis is reported as a side effect among people who take Lumigan (bimatoprost), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Combigan, and have Dry eyes.

The phase IV clinical study analyzes which people have Uveitis when taking Lumigan. It is created by eHealthMe based on reports of 20,141 people who have side effects when taking Lumigan from the FDA, and is updated regularly.

What is Lumigan?

Lumigan has active ingredients of bimatoprost. It is often used in glaucoma. eHealthMe is studying from 20,478 Lumigan users. Check the latest studies of Lumigan.

What is Uveitis?

Uveitis (inflammation of the uvea) is found to be associated with 830 drugs and 1,530 conditions by eHealthMe. Check the latest studies of Uveitis.

On Jul, 26, 2026

20,141 people reported to have side effects when taking Lumigan.
Among them, 90 people (0.45%) have Uveitis.

Among these 90 people:

How long have people been on Lumigan when they have Uveitis? *

What is the gender of people who have Uveitis when taking Lumigan? *

female: 45.68 %
male: 54.32 %

What is the age of people who have Uveitis when taking Lumigan? *

What are other drugs people take besides Lumigan? *

What are other side effects people have besides Uveitis? *

Intraocular Pressure Increased: 17 people, 18.89%
Eye Pain: 14 people, 15.56%
Visual Acuity Reduced (reduced clearness of vision): 14 people, 15.56%
Ocular Hyperaemia (an abnormally large amount of blood in eye): 10 people, 11.11%
Vision Blurred: 9 people, 10.00%
Drug Ineffective: 8 people, 8.89%
Photophobia (extreme sensitivity to light): 6 people, 6.67%
Eye Inflammation: 6 people, 6.67%
Eye Irritation: 6 people, 6.67%
Vitreous Floaters (spots before the eyes): 5 people, 5.56%

What are the existing conditions these people have? *

Age-Related Macular Degeneration: 4 people, 4.44%
Dry Eyes (lack of adequate tears): 4 people, 4.44%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 3 people, 3.33%
Normal Tension Glaucoma (a unique condition in which optic nerve damage and vision loss have occurred despite a normal pressure inside the eye): 3 people, 3.33%
Intraocular Pressure Increased: 2 people, 2.22%
Angle Closure Glaucoma (term used for several ocular diseases that ultimately result in increased intraocular pressure (iop) and decreased visual acuity): 2 people, 2.22%
Arthritis Reactive (autoimmune condition that develops in response to an infection in another part of the body): 2 people, 2.22%
Diarrhea: 2 people, 2.22%
Glucocorticoid Deficiency (less glucocorticoids secretion from kidney): 2 people, 2.22%
Hiv Infection: 2 people, 2.22%

* Approximation only. Some reports may have incomplete information.

Do you take Lumigan and have Uveitis?

- Check whether Uveitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lumigan:

Lumigan (20,478 reports)

Uveitis treatments and more:

Uveitis (29,545 reports)

Browse all side effects of Lumigan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Uveitis:

Uveitis (830 drugs)

Browse all the conditions that are associated with Uveitis:

Uveitis (1,530 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on bimatoprost (the active ingredients of Lumigan) and Lumigan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.